APO-NADOLOL DIN 00782505
Health Canada record
| Active ingredient(s) | NADOLOL 40 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C07AA12 NADOLOL |
| Original market date | 31-Dec-1988 |
| Current status date | 05-Nov-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Apotex Inc — licence 100375, currently licensed, last inspection rating C (2026-04-21).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing NADOLOL
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00782467 | APO-NADOLOL | APOTEX INC | Tablet | NADOLOL 80 MG | Marketed |
| 00782475 | APO-NADOLOL | APOTEX INC | Tablet | NADOLOL 160 MG | Marketed |
| 02496399 | MINT-NADOLOL | MINT PHARMACEUTICALS INC | Tablet | NADOLOL 80 MG | Marketed |
| 02496380 | MINT-NADOLOL | MINT PHARMACEUTICALS INC | Tablet | NADOLOL 40 MG | Marketed |
| 00523372 | CORGARD TAB 160MG | BRISTOL-MYERS SQUIBB CANADA | Tablet | NADOLOL 160 MG | Cancelled Post Market |
| 00607126 | CORGARD TAB 40MG | BRISTOL-MYERS SQUIBB CANADA | Tablet | NADOLOL 40 MG | Cancelled Post Market |
| 00463256 | CORGARD TAB 80MG | BRISTOL-MYERS SQUIBB CANADA | Tablet | NADOLOL 80 MG | Cancelled Post Market |
| 00593338 | CORZIDE TAB W NADOLOL 40MG | SQUIBB CANADA INC., DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | Tablet | NADOLOL 40 MG; BENDROFLUMETHIAZIDE 5 MG | Cancelled Post Market |
| 00593311 | CORZIDE TAB W NADOLOL 80MG | SQUIBB CANADA INC., DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | Tablet | NADOLOL 80 MG; BENDROFLUMETHIAZIDE 5 MG | Cancelled Post Market |
| 00818720 | NADOLOL-160 TAB 160MG | PRO DOC LIMITEE | Tablet | NADOLOL 160 MG | Cancelled Post Market |
| 00828815 | NADOLOL-40 TAB 40MG | PRO DOC LIMITEE | Tablet | NADOLOL 40 MG | Cancelled Post Market |
| 00818704 | NADOLOL-80 TAB 80MG | PRO DOC LIMITEE | Tablet | NADOLOL 80 MG | Cancelled Post Market |
| 00851698 | RATIO-NADOLOL TAB 160MG | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | Tablet | NADOLOL 160 MG | Cancelled Post Market |
| 00851663 | RATIO-NADOLOL TAB 40MG | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | Tablet | NADOLOL 40 MG | Cancelled Post Market |
| 00851671 | RATIO-NADOLOL TAB 80MG | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | Tablet | NADOLOL 80 MG | Cancelled Post Market |
| 02126753 | TEVA-NADOLOL | TEVA CANADA LIMITED | Tablet | NADOLOL 40 MG | Cancelled Post Market |
| 02126761 | TEVA-NADOLOL | TEVA CANADA LIMITED | Tablet | NADOLOL 80 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 24173 | 2020-09-02 | New Drug Submission (NDS) | CHANGE IN PRODUCT OWNERSHIP |
| 15698 | 2014-06-06 | Supplement to a New Drug Submission (SNDS) | PRODUCT NAME CHANGE |
| 15547 | 2014-04-29 | New Drug Submission (NDS) | TRANSFER OF DRUG IDENTIFICATION NUMBERS |
International API supply for NADOLOL
3 valid EDQM Certificates of Suitability from 3 holders. 4 active FDA Drug Master Files.
Request a quote for APO-NADOLOL